Latest News

Tools and Resources Articles

Filter by:
Topic
Clear filter
Tools and Resources

Standardization of IDS Key Performance Indicators and Metrics; Results of a HOPA IDS SIG Survey

April 10, 2024

The Hematology/Oncology Pharmacy Association has helped establish practical guidance for Investigational Services metrics and site utilization.

X-ray of brain with desmoid tumors
Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Nirogacestat (Ogsiveo)

December 27, 2023

Brooke Lochridge, PharmD ,PGY-2 Oncology Pharmacy Resident, of Tristar Centennial Medical Center, Nashville, TN, and Colleen McCabe, PharmD, BCOP, Oncology Clinical Specialist, Sarcoma & Melanoma from Vanderbilt University Medical Center, Nashville, TN w

high-risk neuroblastoma
Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Eflornithine for High-Risk Neuroblastoma

December 13, 2023

Taylor Gullickson, PharmD, PGY1 Pharmacy Resident and Alexis Kuhn, PharmD, BCOP, Pediatric Oncology Pharmacist, from Mayo Clinic Rochester, Minnesota write about Eflornithine for High-Risk Neuroblastoma.

close up photo of colon cancer cells
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Fruquintinib

December 08, 2023

Hunter Sowell, PharmD, PGY-2 Oncology Pharmacy Resident and Sarah Cimino, PharmD, BCOP, Clinical Pharmacist Specialist, Gastrointestinal Oncology, both from Vanderbilt University Medical Center, write about fruquintinib.

Woman pointing to x-ray of metastatic breast cancer diagram
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Capivasertib

November 26, 2023

Rachel B Allen, PharmD, PGY1 Pharmacy Resident and Sarah Cimino, PharmD, BCOP, Clinical Pharmacist Specialist, Gastrointestinal Oncology, both from Vanderbilt University Medical Center, write about Capivasertib.

Tools and Resources Late Breaking News

Immune Checkpoint Inhibitors Make Great Strides in Hepatocellular Carcinoma

May 18, 2023

STRIDE presents an alternative first-line choice for patients with unresectable HCC with a manageable side effect profile and a 22% reduction in risk of death over sorafenib

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Retifanlimab-dlwr

March 22, 2023

Bernard Marini, PharmD, BCOP, Clinical Pharmacist Specialist at University of Michigan College of Pharmacy writes about Retifanlimab-dlwr.

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Pirtobrutinib

January 27, 2023

Andy Hawn, 2025 PharmD Candidate and Erin Kelley, PharmD, BCOP at the Masonic Cancer Clinic Infusion Pharmacy write about Pirtobrutinib

Tools and Resources Late Breaking News

BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

January 18, 2023

BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Mosunetuzumab

December 22, 2022

Bernard Marini, PharmD, BCOP Clinical Pharmacist Specialist – Hematology/Oncology Clinical Associate Professor University of Michigan College of Pharmacy writes about Mosunetuzumab.

Imaging scan of lung cancer
Tools and Resources Drug Updates

Pharmacist Application to Practice: Adagrasib

December 22, 2022

Sam Palmatier, Pharmacy Intern and Jeff Engle, PharmD, MS, Oncology Pharmacy Manager at Fairview Cancer Clinic – Edina write about

Scan of human lungs
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Tremelimumab

November 10, 2022

Tremelimumab (IMJUDO, AztraZeneca Pharmaceuticals) approved November 10, 2022 for metastatic non-small cell lung cancer and approved October 24, 2022 for unresectable hepatocellular carcinoma